Celebrating Two Years in Malaysia: New Vision Display's Manufacturing Expansion Supports Greater Customer Growth and Resilience
ROSEVILLE, Calif., May 6, 2025 /PRNewswire/ -- New Vision Display (NVD), a Shenzhen-based company, is celebrating two years of successful manufacturing operations at its Malaysia facility — a major milestone in the company's strategy to better support customer growth, mitigate risk, and strengthen supply chain resilience across the Southeast Asia region and beyond.
After more than a year of careful research across multiple Southeast Asian countries, NVD formally established its Malaysian entity, NVD (M) SDN. BHD., in August 2022. Factors such as cost, operational efficiency, supply chain stability, workforce readiness, and language accessibility contributed to the selection. NVD's prior experience doing business in Malaysia, along with strong ties to the region through senior leadership from Malaysia and Singapore, further supported the decision.
At the time, global supply chains were still under pressure from the impacts of the COVID-19 pandemic. By establishing operations in Malaysia, NVD provided customers with improved production flexibility, reduced lead times, and greater regional support. Despite travel restrictions that initially delayed operations, NVD successfully launched its screen protector production lines in December 2022, followed by the expansion into Liquid Crystal Module (LCM) and touch panel production in June 2024.
Today, NVD Malaysia plays a critical role in delivering high-quality, customized display solutions that help customers bring innovative products to market faster and more efficiently.
The Malaysia facility spans 10,000 square meters (107,639 square feet) and is ISO9001, ISO14001, and ISO45001 certified, demonstrating NVD's commitment to providing customers with world-class quality, environmental responsibility, and workplace safety standards.
"Setting up NVD (M) SDN. BHD. and growing our production capabilities in Malaysia has allowed us to better align with our customers' evolving needs," said David Kruse, CEO of NVD. "Over the past two years, our Malaysia operations have enhanced our ability to provide strategic, agile support and strengthen the global supply chains that our OEM partners rely on."
With a strong foundation in place, NVD Malaysia continues to expand its capabilities to meet future customer demands and drive shared success around the world.
Contact:
Aubree Abernethy
2242683342
394725@email4pr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, Reckitt, and Tempus and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vestis (VSTS), Reckitt (RBGLY), or Tempus (TEM) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vestis Corporation (NYSE:VSTS), Reckitt Benckiser Group plc (OTC:RBGLY), and Tempus AI, Inc. (NASDAQ: TEM). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Vestis Corporation (NYSE:VSTS) Class Period: May 2, 2024 – May 6, 2025 Lead Plaintiff Deadline: August 8, 2025 According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Vestis' ability to grow its business; notably that Vestis would be unable to execute on planned strategic initiatives to drive purported improvements to the customer experience and its onboarding efforts in order to drive new customer growth, increased customer retention, and increased revenue from existing customers. On May 7, 2025, Vestis announced its financial results for the second quarter of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year 2025, and provided guidance for the third quarter of fiscal 2025 that fell significantly below market expectations. The Company attributed its poor results partially to 'lost business in excess of new business,' but primarily on 'lower adds over stops, which is how we describe volume changes with our existing customers.' The Company attributed its decision to pull full-year guidance and provide disappointing third quarter targets to the 'increasingly uncertain macro environment.' Following this news, the price of Vestis' common stock declined dramatically. From a closing market price of $8.71 per share on May 6, 2025, Vestis' stock price fell to $5.44 per share on May 7, 2025, a decline of about 37.54% in the span of just a single day For more information on the Vestis class action go to: Reckitt Benckiser Group plc (OTC:RBGLY) Class Period: January 13, 2021 – July 28, 2024 Lead Plaintiff Deadline: August 4, 2025 Reckitt is a United Kingdom-based, global consumer goods company. To date, over 500 state and federal products liability lawsuits have been filed against Reckitt and its competitor, Abbott Laboratories ('Abbott'), claiming that they failed to adequately warn that premature infants consuming cow milk-based formulas, such as Reckitt's Enfamil and Abbott's Similac, have an increased risk of developing necrotizing enterocolitis ('NEC'), a life-threatening intestinal disease that affects premature or low birth weight infants. The Class Action alleges that, during the Class Period, Defendants made misleading statements and omissions regarding the Company's business, financial condition, and prospects. Specifically, Defendants failed to warn investors and consumers: (1) that preterm infants were at an increased risk of developing NEC by consuming Reckitt's cow's milk-based formula, Enfamil; (2) of the attendant impact on Reckitt's sales of Enfamil and Reckitt's exposure to legal claims; and (3) as a result of the above, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. For more information on the Reckitt Bensicker class action go to: Tempus AI, Inc. (NASDAQ: TEM) Class Period: August 6, 2024, and May 27, 2025 Lead Plaintiff Deadline: August 11, 2025 According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. For more information on the Elevance class action go to: About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, Walker, Esq. Marion Passmore, Esq.(212) 355-4648 [email protected]
Business Insider
3 hours ago
- Business Insider
Upcoming Stock Splits This Week (July 21 to July 25)
These are the upcoming stock splits for the week of July 21 to July 25 on TipRanks' Stock Splits Calendar. A stock split is a corporate move that increases the number of outstanding shares by issuing more to existing shareholders, all while keeping the company's total market value unchanged. This leads to a lower share price, making the stock more accessible and often more appealing to retail investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. On the flip side, some companies opt for a reverse stock split. Instead of dividing shares, they consolidate them, reducing the share count and boosting the price per share. While the market cap stays the same, this move is typically aimed at meeting minimum price requirements to maintain exchange listings, like Nasdaq's threshold, and avoid delisting. Whether the goal is to attract retail interest or preserve listing status, these corporate maneuvers can send important signals – and smart traders are always watching. Let's take a look at the upcoming stock splits for the week. Invo Fertility (IVF) – Invo Fertility, known for its innovative fertility treatments and its unique INVOcell device, is taking steps to stay in line with Nasdaq's listing requirements. On July 17, the company announced a 1-for-3 reverse stock split to help boost its share price and maintain compliance with the exchange's minimum bid rule. The split will take effect on July 21. Globavend Holdings (GVH) – Australia-based Globavend Holdings offers cross-border logistics services to e-commerce retailers, focusing on last-mile delivery and freight forwarding. On July 17, the company announced a 1-for-200 reverse stock split of its ordinary shares to increase its share price and meet Nasdaq's continued listing standards. GVH stock is expected to begin trading on a split-adjusted basis on July 21. Top Wealth Group Holding (TWG) – Hong Kong-based Top Wealth Group is engaged in environmental consulting, caviar production, and waste treatment services. On July 17, the company announced a 1-for-90 reverse stock split of its ordinary shares to regain compliance with Nasdaq's $1 minimum bid price rule and support its pending merger with Jilin Xiuzheng Agriculture & Animal Husbandry. TWG stock is expected to begin trading on a split-adjusted basis on July 21. CNS Pharmaceuticals (CNSP) – CNS Pharmaceuticals is a biotechnology company focused on developing anticancer drugs for primary and metastatic cancers of the brain and central nervous system. On July 15, the company announced a 1-for-12 reverse stock split of its common shares to comply with Nasdaq's minimum bid requirement. CNSP stock is expected to begin trading on a split-adjusted basis on July 22. Generation Bio (GBIO) – Focused on tackling rare and common genetic diseases, Generation Bio is developing next-gen non-viral gene therapies using its own closed-ended DNA platform. On July 18, the company announced a 1-for-10 reverse stock split to boost its share price and stay in compliance with Nasdaq listing rules. GBIO shares will begin trading on a split-adjusted basis starting July 22. Premium Catering Holdings (PC) – Serving up large-scale halal meals across Asia, Premium Catering Holdings is a key player in feeding construction crews and corporate events alike. On July 17, the Hong Kong-based company announced a 1-for-9 reverse stock split of its ordinary shares, a move aimed at boosting its share price and staying in line with Nasdaq's listing standards. PC stock is set to start trading on a split-adjusted basis on July 22.
New York Post
4 hours ago
- New York Post
Development black hole remains on West 57th Street
If West 57th Street between Sixth and Seventh avenues exemplifies Manhattan's regenerative energy, the block east between Fifth and Sixth avenues remains a black hole of development ambition. The 900-foot-long block — longer than three and a half midtown north-south blocks — looks gloomier every year as landowners hold out for magic-bullet combos of tenant commitments and construction financing. West of Bergdorf Goodman and the Crown Building stretches a procession of vacant lots, empty storefronts and scaffolding. At least four enormous sites await activity. Developers including Vornado, Lefrak, Soloviev, and at least one unknown outfit have kept their sites barren for years. There is a string of vacant lots, empty storefronts and scaffolding on West 57th Street west of Bergdorf Goodman and the Crown Building. New York Post At least four enormous sites await activity. New York Post The latest blows to the block were the closings of Brasserie 8 and a Half at Soloviev's 9 West and Rue 57 at the western corner. The opening soon of a small Abel Richard handbags boutique at 7 West is more than offset by large retail vacancies on either side of Nobu at 40 W. 57th and at the former locations of Mangia and other shops and cafes. Manhattan-based developer Sedesco, meanwhile, is demolishing a building to enlarge a site it's been assembling for more than 10 years between 37-47 W. 57th St. The supertall, mixed-use project is to be designed by 'starchitect' Rem Koolhaas' OMA studio. It will likely re-energize its surroundings. But no construction plans have yet been filed with the Department of Buildings.
